IngenOx Therapeutics, the Oxford biopharma company focused on developing novel cancer therapeutics, provided today a company update on its board reshuffle.
In the revised board, Patrick Soon-Shiong, M.D. joins as Chairman. Leonard S. Sender, M.D. and Sandeep “Bobby” Reddy, M.D. join as non-executive directors. Professors Nick La Thangue, CEO, David Kerr, CMO and Bill Fleming, VP Finance, remain as board directors. Previous members, James Noble, Dr Simon Kerry and Nick Dixon-Clegg are stepping down.
Nick La Thangue, CEO of IngenOx, and Professor of Cancer Biology at the University of Oxford commented:
“We are pleased to welcome our new directors to the IngenOx board, recognising their extensive experience in building successful companies and developing novel cancer assets through approval and commercialisation. These changes in directorship reflect the next stage in the growth of the company. I would like to thank our departing directors for their support and wise counsel in recent years.”
Patrick Soon-Shiong, M.D, Executive Chairman of ImmunityBio commented:
“I am excited to assume the role as Chair of the Board and honoured to be working with the IngenOx team. Their asset portfolio is truly exciting and offers tremendous opportunities for developing novel agents that target new pathways in tumour immunology. Together with our colleagues Drs Sender and Reddy, the revised board is set to support IngenOx’s team and help realise the significant value in the company’s pipeline.”
David Kerr, CMO of IngenOx commented:
“This evolution of our Board brings extraordinary intelligence and clinical experience to bear on the development paths for our exciting immunotherapeutic portfolio. I could not imagine a better brain’s trust to work with us to deliver impactful cancer therapy which will make a real difference to the patients I see in the clinic.”
NOTES:
About IngenOx Therapeutics
IngenOx Therapeutics is a bio-pharmaceutical company focused on delivering new precision medicine drugs and vaccines to treat the most difficult cancers, often referred to as cold tumours. It is a spinout from the University of Oxford, and is located in the Oxford Science Park, UK. Its pipeline comprises early to late-stage products that work in different ways to activate the immune response against cold tumours, which are generally poorly recognised by the immune system.
The company’s approach seeks to align the right drug with the right patient enabling a targeted precision medicine approach to cancer therapy. It has also built a proprietary platform around re-educating the body’s immune system to recognise and destroy tumours. The assets in its pipeline have displayed convincing clinical benefits to late-stage cancer patients through disease control, tumour shrinkage, reduced side effects, and extended survival ti
The company has secured multiple rounds of investment and has numerous license and partnership agreements in place.